Literature DB >> 23038658

Possible involvement of host defense mechanism in the suppression of rat acute reflux esophagitis by the particular histamine H2 receptor antagonist lafutidine.

Motoko Nakano1, Hirofusa Ajioka, Masaaki Abe, Mamoru Kiniwa.   

Abstract

AIMS: Gastroesophageal reflux disease is considered to be caused primarily by gastric juice refluxed into the esophagus. Here, we investigated the possible involvement of host defense mechanisms in the development of acute reflux esophagitis using lafutidine, a histamine H(2) receptor antagonist (H(2)RA) with proven gastric mucosal protective effects. METHODS AND
RESULTS: The ligation of both the pylorus and the forestomach of SD rats under anesthesia caused hemorrhagic lesions in the esophageal mucosa at 6 h. Lesion formation was significantly inhibited by treatment with H(2)RAs, including the conventional H(2)RAs famotidine and cimetidine as well as lafutidine. The maximum suppressive abilities of these agents were similar to that of the proton pump inhibitor lansoprazole. Interestingly, unlike famotidine, lafutidine at low doses significantly suppressed esophagitis without inhibiting gastric acid secretion. Note that neither lafutidine nor famotidine inhibited hexosamine output in gastric juice samples obtained 3 h after ligation. Additionally, the protective effect of lafutidine, but not of famotidine, was partly attenuated by the denervation of capsaicin-sensitive afferent nerves with a large dose of capsaicin.
CONCLUSION: The present results indicate that esophageal host-defense via capsaicin-sensitive afferent nerves may contribute to the therapeutic action of lafutidine.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23038658     DOI: 10.1159/000342386

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

Review 1.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

2.  Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial.

Authors:  Eun Hye Kim; Yong Chan Lee; Young Woon Chang; Jong-Jae Park; Hoon Jai Chun; Hwoon-Yong Jung; Hyun-Soo Kim; Hyun Yong Jeong; Sang-Young Seol; Sok Won Han; Myung-Gyu Choi; Soo-Heon Park; Ok-Jae Lee; Jin Tae Jung; Dong Ho Lee; Hyun Chae Jung; Soo Teik Lee; Jae Gyu Kim; Sei Jin Youn; Hak Yang Kim; Sang Woo Lee
Journal:  Dig Dis Sci       Date:  2014-12-23       Impact factor: 3.199

3.  Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.

Authors:  Ryuta Takenaka; Hiroyuki Okada; Seiji Kawano; Yoshinori Komazawa; Fumiya Yoshinaga; Shinji Nagata; Masafumi Inoue; Hirohisa Komatsu; Seiji Onogawa; Yoshinori Kushiyama; Shinichi Mukai; Hiroko Todo; Hideharu Okanobu; Noriaki Manabe; Shinji Tanaka; Ken Haruma; Yoshikazu Kinoshita
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

4.  Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia.

Authors:  Somnath Maity; Supriyo Choudhury; Avijit Hazra; Amal Kanti Das
Journal:  Indian J Pharmacol       Date:  2014 Sep-Oct       Impact factor: 1.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.